Total Funding
31
Total FundingPost-IPO Equity raised
Growth Score in past quarter
pts
Heat Score 31 in past quarter
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
78378
Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.
Acquired by 
BioMarin Pharmaceutical
- Petra Duda: Chief Medical Officer
- Soojin Kim: Senior vice president and chief technical operations officer (CTOO)
About the Company
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial
Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.